Page last updated: 2024-12-11

fk 866

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6914657
CHEMBL ID566757
CHEBI ID187413
CHEBI ID94671
MeSH IDM0459006

Synonyms (70)

Synonym
fk-866 ,
DGB ,
(2e)-n-{4-[1-(benzenecarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)prop-2-enamide
2GVJ ,
2G97
apo866
n-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
fk866
apo-866
apo 866
fk 866
daporinad
CHEMBL566757
k 22.175
201034-75-5
(e)-n-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide
CHEBI:187413
bdbm81395
(2e)-n-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)prop-2-enamide
658084-64-1
v71tf6v9m7 ,
unii-v71tf6v9m7
daporinad [inn]
fk866 (apo866)
nsc 751605
AKOS015994576
BCP9000687
(e)-daporinad
(2e)-n-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide
S2799
BRD-K58550667-001-01-2
FD5006
(e)-n-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
CCG-208012
gtpl7745
(e)-n-[4-[1-(benzoyl)piperidin-4-yl]butyl]-3-pyridin-3-ylprop-2-enamide
ES-0047
2-propenamide, n-(4-(1-benzoyl-4-piperidinyl)butyl)-3-(3-pyridinyl)-, (2e)-
daporinad [who-dd]
n-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2e-propenamide
(e)-n-[4-(1-benzoyl-piperidin-4-yl)-butyl]-3-pyridin-3-yl-acrylamide
c24h29n3o2
4O1D
4O1B
fk866 hydrochloride hydrate
mfcd10565943
EX-A430
CHEBI:94671
daporinad(fk866,apo866)
KPBNHDGDUADAGP-VAWYXSNFSA-N
DB12731
nicotinamide phosphoribosyltransferase inhibitor, fk866 - cas 658084-64-1
daporinad (fk866, apo866)
Q27076984
BCP01909
nsc-760442
nsc760442
1198425-96-5
A930135
nsc777194
nsc-777194
NCGC00182868-04
daporinad (apo866)
fk 866;(e)-n-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
A850039
DTXSID101026050
EN300-24106674
n-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
(2e)-n-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
2-propenamide, n-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic data suggest an increase in the plasma Css in relation to the escalation of FK866."( The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.
Burk, K; Hanauske, AR; Holen, K; Hollywood, E; Saltz, LB, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" This effect was less pronounced when FK866 was used in combination with another alkylating agent, melphalan."( Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Azzam, K; Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I, 2006
)
0.33
" In this study we addressed the potential of NAD(+) depletion as an anti-cancer strategy and assessed the combination with radiation."( NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study.
Floot, B; van Triest, B; Vens, C; Verheij, M; Zerp, SF, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" Compound 50 also showed excellent in vivo antitumor efficacy when dosed orally in an A2780 ovarian tumor xenograft model (TGI of 97% was observed on day 17)."( Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Bair, KW; Bauer, P; Baumeister, T; Buckmelter, AJ; Caligiuri, M; Clodfelter, KH; Dragovich, PS; Gunzner-Toste, J; Han, B; Ho, YC; Kley, N; Lin, J; Oh, A; Reynolds, DJ; Sharma, G; Smith, CC; Wang, W; Wang, Z; Yuen, PW; Zak, M; Zhao, G; Zheng, X, 2013
)
0.39
" Modification of the isoindoline and/or the terminal functionality of screening hit 5 provided inhibitors such as 52 and 58 with nanomolar antiproliferative activity and preclinical pharmacokinetics properties which enabled potent antitumor activity when dosed orally in mouse xenograft models."( SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Aguirre, AL; Algire, MA; Badagnani, I; Buchanan, FG; Cheng, D; Cheng, M; Chiang, GG; Clark, RF; Curtin, ML; Doherty, GA; Frey, RR; Guo, J; Hansen, TM; Heyman, HR; Korepanova, AV; Kovar, PJ; Longenecker, KL; Maag, D; Marin, VL; Michaelides, MR; Pliushchev, MA; Raich, D; Richardson, PL; Sarris, KA; Shrestha, A; Soni, NB; Sorensen, BK; Sweis, RF; Tse, C; Tu, N; Vasudevan, A; Wilsbacher, JL; Woller, K, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
benzamides
N-acylpiperidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
NAD+ Signalling Pathway (Cancer)1012
NAD+ Signalling and Aging1110

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GVesicular stomatitis virusPotency13.45040.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency16.93300.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency13.45040.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Nicotinamide phosphoribosyltransferaseHomo sapiens (human)Ki0.00030.00030.00030.0003AID977610
Chain B, Nicotinamide phosphoribosyltransferaseHomo sapiens (human)Ki0.00030.00030.00030.0003AID977610
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.00100.00011.774010.0000AID1327638
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.00100.00011.753610.0000AID1327638
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)0.00100.00002.800510.0000AID1327638
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)0.00100.00002.398310.0000AID1327638
Nicotinamide phosphoribosyltransferaseHomo sapiens (human)IC50 (µMol)0.99550.00010.07102.1000AID1057516; AID1074222; AID1327637; AID1327638; AID1349718; AID1370576; AID1451820; AID1589821; AID1625934; AID1760611; AID1799546; AID1911863; AID589998; AID752617; AID765316
Nicotinamide phosphoribosyltransferaseHomo sapiens (human)Ki0.00240.00020.00250.0060AID1454317; AID1515663; AID1515664; AID767972
Nicotinamide phosphoribosyltransferaseMus musculus (house mouse)IC50 (µMol)0.00380.00270.02270.0590AID1440865; AID1564540
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Nicotinamide phosphoribosyltransferaseRattus norvegicus (Norway rat)Kd0.15200.15200.15200.1520AID977611
Chain B, Nicotinamide phosphoribosyltransferaseRattus norvegicus (Norway rat)Kd0.15200.15200.15200.1520AID977611
Chain A, Nicotinamide phosphoribosyltransferaseRattus norvegicus (Norway rat)Kd0.15200.15200.15200.1520AID977611
Chain B, Nicotinamide phosphoribosyltransferaseRattus norvegicus (Norway rat)Kd0.15200.15200.15200.1520AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (91)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
insulin receptor signaling pathwayNicotinamide phosphoribosyltransferaseHomo sapiens (human)
adipose tissue developmentNicotinamide phosphoribosyltransferaseHomo sapiens (human)
signal transductionNicotinamide phosphoribosyltransferaseHomo sapiens (human)
cell-cell signalingNicotinamide phosphoribosyltransferaseHomo sapiens (human)
positive regulation of cell population proliferationNicotinamide phosphoribosyltransferaseHomo sapiens (human)
circadian regulation of gene expressionNicotinamide phosphoribosyltransferaseHomo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayNicotinamide phosphoribosyltransferaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINicotinamide phosphoribosyltransferaseHomo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processNicotinamide phosphoribosyltransferaseHomo sapiens (human)
NAD biosynthetic processNicotinamide phosphoribosyltransferaseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (53)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
cytokine activityNicotinamide phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinamide phosphoribosyltransferaseHomo sapiens (human)
identical protein bindingNicotinamide phosphoribosyltransferaseHomo sapiens (human)
nicotinamide phosphoribosyltransferase activityNicotinamide phosphoribosyltransferaseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
cytosolNicotinamide phosphoribosyltransferaseHomo sapiens (human)
nuclear speckNicotinamide phosphoribosyltransferaseHomo sapiens (human)
cell junctionNicotinamide phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinamide phosphoribosyltransferaseHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolNicotinamide phosphoribosyltransferaseMus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (162)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2006Journal of molecular biology, Sep-08, Volume: 362, Issue:1
Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866.
AID1811Experimentally measured binding affinity data derived from PDB2006Journal of molecular biology, Sep-08, Volume: 362, Issue:1
Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866.
AID443103Cytotoxicity against human SH-SY5Y cells assessed as reduction of total cellular NAD(P) level2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry.
AID1440908In vivo inhibition of NAMPT in DNBS-induced BALB/c mouse colitis model assessed as reduction in mucosal congestion at 20 mg/kg, ip bid administered for 3 days post DNBS challenge2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1515663Displacement of fluorescent labelled OG488 from human full length FLAG-tagged NAMPT (1 to 491 residues) expressed in HEK293-6E cells in absence of PRPP by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID1440903Antitumor activity against human A2780 cells xenografted in athymic nu/nu Harlan mouse assessed as reduction in tumor growth at 10 mg/kg, ip bid administered for 8 consecutive days2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1057517Resistance factor, ratio of IC50 for APO866-resistant human HCT116 cells to IC50 for human HCT116 cells2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1451849Antitumor activity against human HCT116 cells xenografted in BALB/C nude mouse assessed as tumor growth inhibition at 15 mg/kg, ip bid administered for 21 consecutive days measured after 30 to 33 days post implantation relative to control2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1440900Drug metabolism in athymic Nu/Nu Harlan mouse blood assessed as N-oxide metabolite formation at 10 mg/kg, iv administered as single dose up to 24 hrs by LC-ESI-MS analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1057505Cytotoxicity against human SKOV3 cells by clonogenic assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1564538Cytotoxicity against human SH-SY5Y cells assessed as cell viability at 1 uM measured after 48 hrs by MTT assay relative to control2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID765310Apparent permeability across apical to basolateral side in dog MDCK cells at 10 uM by LC-MS/MS analysis2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
AID1440909In vivo inhibition of NAMPT in DNBS-induced BALB/c mouse colitis model assessed as reduction in erosion at 20 mg/kg, ip bid administered for 3 days post DNBS challenge2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID765312Intrinsic clearance in CD-1 mouse hepatocytes at 1 uM after 10 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
AID1625934Inhibition of recombinant NAMPT (unknown origin) using nicotinamide as substrate measured every 5 mins for 30 mins in presence of recombinant NMNAT12016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID752617Inhibition of Nampt (unknown origin) using NAM/PRPP as substrate preincubated for 15 mins measured after 30 mins2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
AID1564579Kinetic aqueous solubility of the compound in 80:20 PBS/acetonitrile solution at 200 uM by HTS assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1541819Binding affinity to NAMPT in human HCt116 cells assessed as increase in stability of cellular NAMPT at 10 uM preincubated for 2 hrs followed by heating at 49 to 70 degC for 3 mins by Western blot-based CESTA2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID765315Antiproliferative activity against human A2780 cells assessed as growth inhibition after 72 hrs by SRB-based microplate reader analysis2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
AID443099Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry.
AID1911915Antitumor activity against human A549/Taxol cells xenografted in athymic nude mouse assessed as tumor growth inhibition at 10 mg/kg, ip administered once every other day for 21 days in presence of TSA
AID1440875Stability in human liver microsomes after 60 mins by LC-ESI-MS analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1440904Toxicity in athymic nu/nu Harlan mouse xenografted with human A2780 cells assessed as body weight loss at 10 mg/kg, ip bid administered for 8 consecutive days measured through out study2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1057502Half life in NMRI mouse at 20 mg/kg, iv2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1349722Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1057509Cytotoxicity against human MCF7 cells after 96 hrs by clonogenic assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1589825Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
AID1327642Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate in presence of NADPH by LC-MS/MS analysis2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
AID1440898Clearance in athymic Nu/Nu Harlan mouse at 10 mg/kg, iv administered as single dose up to 24 hrs by LC-ESI-MS analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1327641Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
AID1451824Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1057512Cytotoxicity against human A431 cells by clonogenic assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID767971Cytotoxicity against human K562 cells after 96 hrs by MTT assay2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.
AID1057481Antitumor activity against human A2780 cells xenografted in NMRI/nude mouse assessed as tumor growth inhibition at 15 mg/kg, ip bid administered for 5 days measured at day 14 relative to vehicle-treated control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID765311Intrinsic clearance in human hepatocytes at 1 uM after 10 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
AID1440906Antitumor activity against mouse mammary cancer cells allografted in athymic nu/nu Harlan mouse2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID765309Fraction unbound in human plasma at 5 uM after 4 hrs by LC-MS/MS analysis2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
AID1589824Antiproliferative activity against human DU145 cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
AID1349719Inhibition of recombinant full length human C-terminal His/flag-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells after 30 mins by fluorescence assay2018ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID765313Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 30 mins LC-MS analysis2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
AID1564544Clearance in BALB/c mouse at 10 mg/kg, iv administered as single dose measured after 24 hrs by LC-ESI/MS analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1451821Inhibition of human recombinant HDAC1 (1 to 482 residues) expressed in Baculovirus using Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1327638Inhibition of NAMPT in human A2780 cells assessed as decrease in cell viability after 72 hrs by SRB assay2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
AID1760615Inhibition of N-terminal GST-tagged human recombinant EGFR L858R mutant (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID752616Cytotoxicity against human A2780 cells after 72 hrs by SRB assay2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
AID1515665Antiproliferative activity against human PC3 cells assessed as reduction in cell viability by Celltiter-Glo assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID1451820Inhibition of human recombinant NAMPT using NAM as substrate preincubated for 5 mins followed by substrate addition measured after 15 mins by fluorescence assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1564554Toxicity in Crl:CD Sprague-Dawley rat retina at 100 mg/kg, ip administered once daily for 5 days by hematoxylin and eosin staining based microscopic analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1349733Toxicity in BALB/C nude mouse xenografted with human HCT116 cells assessed as body weight loss at 15 mg/kg, ip bid administered for 21 consecutive days measured every 3 days2018ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1589826Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutation assessed as inhibition of cell growth after 72 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
AID1057520Cytotoxicity against human MCF-7 cells assessed as growth inhibition after 72 hrs by WST-1 assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1653849Inhibition of NAMPT (unknown origin) at 10 to 300 uM using NAM and PRPP as substrates incubated for 2 hrs in presence of ATP by fluorimetric plate reader assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
AID589999Cytotoxicity against human SNU638 cells after 6 days by SRB assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
AID767966Cytotoxicity against human NYH cells after 3 weeks by clonogenic survival assay2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.
AID1440877Drug metabolism in Wistar Han rat liver microsomes assessed as mixed function oxidase mediated compound cleavage by measuring compound remaining after 60 mins in presence of NADPH-regenerating system by LC-UV analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1057519Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by WST-1 assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1074215Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay in presence of nicotinamide mononucleotide2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID1440897AUC in athymic Nu/Nu Harlan mouse at 10 mg/kg, iv administered as single dose up to 24 hrs by LC-ESI-MS analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1589821Inhibition of recombinant NAMPT (unknown origin) using NAM and PRPP as substrates incubated for 60 mins in presence of NMNAT1 measured at 5 mins interval for 30 mins by WST1 assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
AID1370576Inhibition of human full length C-terminal flag/His-tagged NAMPT (1 to 491 residues) expressed in HEK293-6E cells by TR-FRET assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Fragment-based discovery of a potent NAMPT inhibitor.
AID1349721Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID589995Antitumor activity against human MCF7 cells after 6 days by SRB assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
AID1454333Aqueous solubility of the compound2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
AID1454317Inhibition of C-terminal His-tagged human recombinant NAMPT using FK866 or isoindoline urea-based Oregon green (488) probe incubated for 3 hrs by TR-FRET assay2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
AID1451822Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1911864Substrate activity at recombinant human NQO1 assessed as reduction in NADPH level measured per umol of NQO1 at 10 uM in presence of NADPH by NADPH recycling assay
AID589997Cytotoxicity against human HCT116 cells after 6 days by SRB assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
AID589993Cytotoxicity against human K562 cells after 6 days by SRB assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
AID1057508Cytotoxicity against human MCF7 cells by clonogenic assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1515664Displacement of fluorescent labelled OG488 from human full length FLAG-tagged NAMPT (1 to 491 residues) expressed in HEK293-6E cells in presence of PRPP by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID1074218Clearance in human liver microsomes at 1 uM up to 60 mins by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID1911863Inhibition of recombinant human NAMPT incubated for 60 mins by colorimetric assay
AID1451823Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1564558Toxicity in Crl:CD Sprague-Dawley rat heart assessed as interstitial expansion at 100 mg/kg, ip administered once daily for 5 days by hematoxylin and eosin staining based microscopic analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1057475Toxicity in human A2780 cells xenografted NMRI/nude mouse containing small tumors assessed as effect on body weight at 15 mg/kg, ip bid administered for 5 days measured at day 14 relative to vehicle-treated control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1760614Inhibition of N-terminal GST-tagged human recombinant EGFR L861Q mutant (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID1074220Aqueous solubility of the compound after 24 hrs by LC/CLND analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID1589822Antiproliferative activity against human K562 cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
AID1760612Inhibition of N-terminal GST-tagged human recombinant EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID1440879Stability in Wistar Han rat liver microsomes assessed as mixed function oxidase mediated compound cleavage after 60 mins in presence of NADPH-regenerating system by LC-UV analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1057511Cytotoxicity against human DU145 cells by clonogenic assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1057498Cmax in NMRI mouse at 20 mg/kg, iv2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1564540Inhibition of recombinant mouse wild-type NAMPT expressed in bacterial expression system using PRPP as substrate in presence of mouse NMNAT-3 measured for 1 hr by fluorescence assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1564539Cytotoxicity against human SH-SY5Y cells measured after 48 hrs by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1057507Cytotoxicity against human PC3 cells by clonogenic assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1440901Apparent aqueous solubility of the compound2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1625939Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1454319Unbound intrinsic clearance in mouse liver microsomes at 0.5 uM in presence of NADPH incubated for 5 to 30 mins by HPLC-MS/MS method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
AID1440880Stability in human liver microsomes assessed as mixed function oxidase mediated compound cleavage after 60 mins in presence of NADPH-regenerating system by LC-UV analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1057504Toxicity in ip dosed NMRI mouse assessed as body weight loss administered as bid for 5 days2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1440866Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 56 hrs by MTT assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1057522Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by WST-1 assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1760613Inhibition of N-terminal GST-tagged human recombinant EGFR T790M mutant (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID1299168Inhibition of NAMPT in neonatal mouse superior cervical ganglion explant assessed as delay in degeneration of injured axons at 100 nM treated <10 mins prior to axon transection meaured at 8 to 24 hrs by phase contrast microscopy2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
AID1057494Clearance in NMRI mouse at 20 mg/kg, iv2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1454318Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 5 days by Cell-titer Glo reagent based assay2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
AID589996Cytotoxicity against human A549 cells after 6 days by SRB assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
AID1057513Cytotoxicity against human A2780 cells by clonogenic assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1515645Permeability of compound in 5% DMSO after 7 hrs by PAMPA2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID1440910In vivo inhibition of NAMPT in DNBS-induced BALB/c mouse colitis model assessed as reduction in hemorrhagic ulcerations at 20 mg/kg, ip bid administered for 3 days post DNBS challenge2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1440896Half life in athymic Nu/Nu Harlan mouse at 10 mg/kg, iv administered as single dose up to 24 hrs by LC-ESI-MS analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1440865Inhibition of recombinant mouse NAMPT expressed in bacterial expression system using nicotinamide as substrate after 1 hr by fluorescence based NMNAT-3 enzyme coupled assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1564543AUC in BALB/c mouse at 10 mg/kg, iv administered as single dose measured after 24 hrs by LC-ESI/MS analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1589823Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
AID1911894Antitumor activity against human A549/Taxol cells xenografted in athymic nude mouse assessed as tumor growth inhibition by measuring relative tumor growth at 10 mg/kg, ip administered once a day for 21 days
AID1349731Antitumor activity against human HCT116 cells xenografted in BALB/C nude mouse assessed as tumor growth inhibition at 15 mg/kg, ip bid administered for 21 consecutive days measured every 3 days2018ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1911893Antitumor activity against human A549/Taxol cells xenografted in athymic nude mouse assessed as tumor growth inhibition at 10 mg/kg, ip administered once a day for 21 days
AID1564545Volume of distribution in BALB/c mouse at 10 mg/kg, iv administered as single dose measured after 24 hrs by LC-ESI/MS analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1911916Antitumor activity against human A549/Taxol cells xenografted in athymic nude mouse assessed as tumor growth inhibition by measuring relative tumor growth at 10 mg/kg, ip administered once every other day for 21 days in presence of TSA
AID1911862Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay
AID1327644Inhibition of CYP2C19 in human liver microsomes using mephenytoin as substrate in presence of NADPH by LC-MS/MS analysis2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
AID1564542Half-life in BALB/c mouse at 10 mg/kg, iv administered as single dose measured after 24 hrs by LC-ESI/MS analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1074222Inhibition of C-terminal His-tagged human full-length NAMPT expressed in Escherichia coli Rosetta DE3 using nicotinamide as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins in presence of PRPP2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID1454320Unbound intrinsic clearance in human liver microsomes at 0.5 uM in presence of NADPH incubated for 5 to 30 mins by HPLC-MS/MS method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
AID765308Fraction unbound in mouse plasma at 5 uM after 4 hrs by LC-MS/MS analysis2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
AID1625937Cytotoxicity against human NCI-H1975 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1349718Inhibition of NAMPT (unknown origin) using NAM as substrate incubated for 5 mins followed by substrate addition measured after 15 mins by fluorometric method2018ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1653848Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
AID1440907In vivo inhibition of NAMPT in DNBS-induced BALB/c mouse colitis model assessed as reduction in loss of body weight at 20 mg/kg, ip bid administered for 3 days post DNBS challenge2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1327637Inhibition of human full length C-terminal His6-tagged NAMPT expressed in Escherichia coli Rosetta (DE3) cells using nicotinamide as substrate incubated for 15 mins prior to substrate addition measured after 30 mins in presence of PRPP2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
AID1625935Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1440883Drug metabolism in Wistar Han rat liver microsomes assessed as pyridine N-oxidation after 60 mins in presence of NADPH-regenerating system by LC-UV analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1564556Toxicity in Crl:CD Sprague-Dawley rat heart assessed as hypereosinophilia at 100 mg/kg, ip administered once daily for 5 days by hematoxylin and eosin staining based microscopic analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1074217Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID1440884Drug metabolism in human liver microsomes assessed as pyridine N-oxidation after 60 mins in presence of NADPH-regenerating system by LC-UV analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1564557Toxicity in Crl:CD Sprague-Dawley rat heart assessed as increase in cardiomyocytes cytoplasmic vacuolation at 100 mg/kg, ip administered once daily for 5 days by hematoxylin and eosin staining based microscopic analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1440905Antitumor activity against mouse fibrosarcoma cells allografted in athymic nu/nu Harlan mouse2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID765314Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM after 30 mins LC-MS analysis2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
AID1057499Tmax in NMRI mouse at 20 mg/kg, iv2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1589827Antiproliferative activity against human HuH7 cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
AID1057493AUC in NMRI mouse at 20 mg/kg, iv2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID589998Inhibition of human NAmPRTase by spectrophotometric analysis2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
AID1057506Cytotoxicity against human NYH cells by clonogenic assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1440899Volume of distribution in athymic Nu/Nu Harlan mouse at 10 mg/kg, iv administered as single dose up to 24 hrs by LC-ESI-MS analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1440876Stability in Wistar Han rat liver microsomes after 60 mins by LC-ESI-MS analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1625936Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID765316Inhibition of C-terminal His-tagged NAMPT (unknown origin) expressed in Escherichia coli BL21 using nicotinamide as substrate preincubated for 15 mins before substrate addition measured after 30 mins by mass spectrometry-based assay2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
AID767972Noncompetitive inhibition of NAMPT (unknown origin)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.
AID1625938Cytotoxicity against human U937 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1057516Inhibition of NAMPT in human HepG2 cells using [14C]-nicotinamide/PRPP as substrate assessed as formation of [14C]-nicotinamide mononucleotide after 1 hr by liquid scintillation counting analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1911873Inhibition of NAD+ biosynthesis in human A549/Taxol cells assessed as decrease in cellular NAD+ level at 15 uM by WST-8 assay
AID1760611Inhibition of recombinant NAMPT (unknown origin) using nicotinamide and pyrophosphate as substrate incubated for 60 mins and measured for 30 mins at 5 mins interval by colorimetric assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID1349720Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1440912In vivo inhibition of NAMPT in DNBS-induced BALB/c mouse colitis model assessed as reduction in neutrophil infiltration by measuring myeloperoxidase levels at 20 mg/kg, ip bid administered for 3 days post DNBS challenge by ELISA2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1440902Cytotoxicity against human A2780 cells assessed as reduction in cell viability2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID443163Induction of autophagy in human SH-SY5Y cells assessed as LC3/phosphotidylethanolamine coupling after 40 hrs by Western blot analysis2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry.
AID1440878Drug metabolism in human liver microsomes assessed as mixed function oxidase mediated compound cleavage by measuring compound remaining after 60 mins in presence of NADPH-regenerating system by LC-UV analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID1057503Toxicity in ip dosed NMRI mouse assessed as blood cell count administered as bid for 5 days2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID589994Antitumor activity against human MCF7 cells at 10 uM after 6 days by SRB assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
AID1327639Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
AID1440911Downregulation of NAMPT expression in DNBS-induced BALB/c mouse colitis model at 20 mg/kg, ip bid administered for 3 days post DNBS challenge by Western blot analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID589992Cytotoxicity against human HT1080 cells after 6 days by SRB assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
AID1327640Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
AID1564541Permeability across apical side to basolateral side in human Caco2 cells at 30 uM after 4 hrs by HPLC analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID1057518Cytotoxicity against APO866-resistant human HCT116 cells assessed as growth inhibition after 72 hrs by WST-1 assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1057497Apparent volume of distribution in NMRI mouse at 20 mg/kg, iv2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
AID1799546In Vitro Inhibition Assay from Article 10.1016/j.chembiol.2010.05.008: \\Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound.\\2010Chemistry & biology, Jun-25, Volume: 17, Issue:6
Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2014PloS one, , Volume: 9, Issue:10
Structural basis for resistance to diverse classes of NAMPT inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2006Nature structural & molecular biology, Jul, Volume: 13, Issue:7
Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2006Nature structural & molecular biology, Jul, Volume: 13, Issue:7
Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (186)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's22 (11.83)29.6817
2010's138 (74.19)24.3611
2020's26 (13.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.87 (24.57)
Research Supply Index5.26 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index47.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.60%)5.53%
Reviews4 (2.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other181 (96.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]